Business
New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America
New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America.
About this update from Sustainable Green Team, Ltd.
[{"type":"text","content":"\r\n\r\n \r\n \r\n New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America\r\n \r\n \r\n\r\n\r\nNew to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America\r\n\r\n\r\n\r\n\r\n\r\nCommercial Sponsors\r\n Tonight's broadcast includes commercial placements from:\r\n NeOnc Technologies Holdings Inc. (NASDAQ:NTHI)\r\n Synergy CHC Corp. (NASDAQ:SNYR)\r\n Sustainable Green Team Ltd. (OTC:SGTM)\r\n YY Group Holding Limited (NASDAQ:YYGH) NEW YORK CITY, NEW YORK / ACCESS Newswire / February 21, 2026 / \r\n \r\n \r\n \r\n New to The Street to Broadcast Executive Leadership Interviews Across the U.S., MENA and Latin America on Bloomberg Television\r\n New to The Street announces that its latest episode will air tonight at 6:30 PM EST on Bloomberg Television in the United States as sponsored programming.\r\n The program will also broadcast internationally at 12:30 PM local time across MENA (Middle East and North Africa) and Latin America, extending the show's global reach to additional financial markets and international investor audiences.\r\n The episode features executive interviews with public companies spanning biotechnology, healthcare innovation, immersive technology, veterinary medicine, and consumer health, highlighting clinical milestones, growth initiatives, and capital markets positioning.\r\n Featured Executive Interviews\r\n BioVie Inc. (NASDAQ:BIVI)\r\n BioVie is advancing clinical-stage therapies for Parkinson's disease, Long COVID, and advanced liver disease.\r\n Fully enrolled Phase 2 Parkinson's trial (60 patients) evaluating Bezy\r\n Targeting both motor and non-motor symptoms\r\n Novel anti-inflammatory mechanism with potential disease-modifying implications\r\n Topline data expected May 2026\r\n The company is also enrolling rapidly in a Long COVID study at leading U.S. academic centers and preparing financing strategies to initiate a Phase 3 Ascites trial later this year.\r\n Vivos Therapeutics Inc. (NASDAQ:VVOS)\r\n Vivos addresses obstructive sleep apnea (OSA), a condition estimated to affect one billion people globally.\r\n FDA-cleared non-surgical oral appliance\r\n Airway remodeling methodology\r\n Designed as a long-term solution fo...